 CHARLESTON, S.C., Feb. 16, 2021 GLOBE NEWSWIRE -- Aeterna Zentaris Inc. NASDAQ: AEZS TSX: AEZS Aeterna or the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 20,509,746 common shares of Aeterna, at a price to the public of 1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions. 